SpyGlass Pharma, Inc. Common Stock (SGP) Stock Analysis & Investment Frameworks
SpyGlass Pharma, Inc. Common Stock (SGP) stock analysis on Invetso. Review SpyGlass Pharma, Inc. Common Stock’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
SpyGlass Pharma, Inc. Common Stock Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
SpyGlass Pharma, Inc. Common Stock Key Financial Metrics
- Market Cap: $879.68M
- Revenue: $N/A
- ROE: -75.64%
- ROIC: -26.54%
- Dividend Yield: N/A
About SpyGlass Pharma, Inc. Common Stock
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.